Ruth Diazaraque

VP, Research and Development

Ruth Diazaraque is Vice President, Research and Development of Alexion, AstraZeneca Rare Disease.


About Ruth

Ruth brings more than 20 years of experience across the biopharmaceutical industry to Alexion, where she oversees our pipeline investment strategy. Prior to Alexion, she served as VP, Senior Medical Officer, Regional Medical & Scientific Affairs at Parexel guiding drug development strategy. She also served as VP Medical Affairs, Head of Regions at BioMarin leading strategic planning and tactical execution of all Medical Affairs across the company’s Rare Disease portfolio. Earlier in her career, Ruth held roles at Gilead Sciences, Pfizer and GlaxoSmithKline. She has also held an honorary consultant position at Chelsea and Westminster Hospital.

Ruth, a licensed physician, holds a MD and PhD in Medicine from Universidad Autonoma de Madrid and an MS in Methodology and Statistics in Health Sciences from Universidad Autonoma de Barcelona. Ruth has an MBA from the IE Business School Madrid and an MS in Pharmaceutical Medicine from Hibernia University in Dublin.

Albie, diagnosed with LAL-D as an infant, riding a bike
My hope is that he carries on being the way he is now, so he gets better. I just feel proud. He’s fought for himself, he’s been strong.”